Comparison
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 vs 3mc Syndrome 2 C0796279
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Endogenous Maternal Derived Androgen and 3mc Syndrome 2 for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
A condition where hormones from the mother cross the placenta and cause atypical development in an XX fetus. It is present at birth. Management involves pediatric specialists and may include hormone therapy.
3mc Syndrome 2 C0796279
A rare genetic condition similar to other 3MC types, affecting multiple systems with facial, developmental, and growth manifestations. Treatment focuses on symptom management.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
Variable
3mc Syndrome 2 C0796279
0-0
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
severe
3mc Syndrome 2 C0796279
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
Chronic
3mc Syndrome 2 C0796279
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
No
3mc Syndrome 2 C0796279
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
reproductive
3mc Syndrome 2 C0796279
congenital
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
endocrine
3mc Syndrome 2 C0796279
genetic
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-endogenous-maternal-derived-androgen-C5679875 and 3mc-syndrome-2-C0796279 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 | 3mc Syndrome 2 C0796279 | Discriminating power |
|---|---|---|---|
| Genital development | Atypical genital development in an XX fetus may be present at birth. | Genital atypicality is not established as a defining feature from the supplied data. | Moderate |
| Facial and growth features | Multisystem facial, developmental, or growth findings are not described. | Facial, developmental, and growth manifestations may affect multiple systems. | High |
| Timing of recognition | Described as present at birth, although onset is listed as variable. | Source onset is recorded as 0-0, suggesting congenital recognition but not a precise course. | Low |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 when
XX infant with atypical genital development
The supplied description centers on placental transfer of maternal-derived androgen.
Moderate
Suspected maternal androgen source
Endocrine evaluation is more relevant than a primary multisystem genetic syndrome.
Moderate
Need for pediatric endocrine and DSD care
Management is described as specialist-led and may include hormone therapy.
High
Choose 3mc Syndrome 2 C0796279 when
Congenital multisystem pattern
3MC syndrome 2 is described as genetic with facial, developmental, and growth features.
Moderate
Family or genetic evaluation is indicated
Its category is genetic rather than an endocrine exposure condition.
Moderate
Symptom-focused supportive care
Treatment is described as management of manifestations, without a specified disease-modifying therapy.
Low
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875 | 3mc Syndrome 2 C0796279 | Interpretation |
|---|---|---|---|
| Karyotype or sex-chromosome assessment | 46,XX is part of the concept name, but confirmation is required. | No specific karyotype result is established by the supplied data. | A chromosome result supports classification but does not prove the cause. |
| Endocrine assessment | Maternal and infant androgen evaluation may be considered by specialists. | No characteristic endocrine abnormality is supplied. | Abnormal hormone results are findings, not a complete diagnosis. |
| Genetic testing | Not established as the primary test from the source description. | Genetic evaluation may be relevant because the condition is categorized as genetic. | Test selection and interpretation require a clinician and genetics specialist. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Endogenous Maternal Derived Androgen C5679875
- Outcome
- Long-term outcome is not established; the condition is described as severe and chronic.
- Factors
- Specialist management and possible hormone therapy are mentioned, without outcome data.
3mc Syndrome 2 C0796279
- Outcome
- Outcome is not established; it is described as moderate, chronic, and symptom-managed.
- Factors
- Extent of facial, developmental, and growth manifestations may influence needs.
Time frame: Both are congenital or present early, but no reliable time course is supplied.
Prognosis should be individualized; no mortality or response rates are available here.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental impact | Potential effects relate mainly to sex development; broader outcomes are not established. Developmental manifestations are described, but severity and trajectory are unspecified. No prevalence or functional outcome data are supplied. |
| Growth concerns | Growth effects are not described in the source. Growth manifestations are part of the supplied description. Exact growth parameters should not be inferred. |
| Long-term medical needs | Chronic specialist follow-up and possible hormone therapy are described. Chronic symptom management across affected systems may be needed. Neither description establishes complication rates or mortality. |
Patient education highlights
- HighDiagnosis is specialist-led
These labels describe different conditions; test results and exam findings need clinician interpretation.
- HighNo self-directed treatment
Do not start, stop, or adjust hormones or other treatment without the pediatric care team.
- MediumSupportive follow-up
Ask about endocrine, genetics, developmental, and psychosocial referrals appropriate to the confirmed condition.